Isogenic cell models of cystic fibrosis-causing variants in natively expressing pulmonary epithelial cells.

[1]  H. Bihler,et al.  High-Throughput Screening for Readthrough Modulators of CFTR PTC Mutations , 2017, SLAS technology.

[2]  G. Lukács,et al.  Correctors and Potentiators Rescue Function of the Truncated W1282X-Cystic Fibrosis Transmembrane Regulator (CFTR) Translation Product*♦ , 2016, The Journal of Biological Chemistry.

[3]  B. Conklin,et al.  Systematic quantification of HDR and NHEJ reveals effects of locus, nuclease, and cell type on genome-editing , 2016, Scientific Reports.

[4]  David Y. Thomas,et al.  Low free drug concentration prevents inhibition of F508del CFTR functional expression by the potentiator VX‐770 (ivacaftor) , 2016, British journal of pharmacology.

[5]  Gabor T. Marth,et al.  A global reference for human genetic variation , 2015, Nature.

[6]  Nikhil T. Awatade,et al.  Measurements of Functional Responses in Human Primary Lung Cells as a Basis for Personalized Therapy for Cystic Fibrosis , 2014, EBioMedicine.

[7]  D. Bedwell,et al.  Therapeutics based on stop codon readthrough. , 2014, Annual review of genomics and human genetics.

[8]  S. McColley,et al.  A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. , 2014, The Lancet. Respiratory medicine.

[9]  E. Lander,et al.  Development and Applications of CRISPR-Cas9 for Genome Engineering , 2014, Cell.

[10]  L. Maquat,et al.  The Dharma of Nonsense-Mediated mRNA Decay in Mammalian Cells , 2014, Molecules and cells.

[11]  James E. DiCarlo,et al.  RNA-Guided Human Genome Engineering via Cas9 , 2013, Science.

[12]  Le Cong,et al.  Multiplex Genome Engineering Using CRISPR/Cas Systems , 2013, Science.

[13]  A. Gopalsamy,et al.  Identification of pyrimidine derivatives as hSMG-1 inhibitors. , 2012, Bioorganic & medicinal chemistry letters.

[14]  M. Drumm,et al.  Genetic variation and clinical heterogeneity in cystic fibrosis. , 2012, Annual review of pathology.

[15]  P. Negulescu,et al.  Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809 , 2011, Proceedings of the National Academy of Sciences.

[16]  F. van Goor,et al.  Use of primary cultures of human bronchial epithelial cells isolated from cystic fibrosis patients for the pre-clinical testing of CFTR modulators. , 2011, Methods in molecular biology.

[17]  B. Kerem,et al.  Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin. , 2007, The Journal of clinical investigation.

[18]  J. Cassiman,et al.  Established cell lines used in cystic fibrosis research. , 2004, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[19]  L. Chin,et al.  CFTR expression and chloride secretion in polarized immortal human bronchial epithelial cells. , 1994, American journal of respiratory cell and molecular biology.

[20]  A. Hamosh,et al.  CFTR nonsense mutations G542X and W1282X associated with severe reduction of CFTR mRNA in nasal epithelial cells. , 1992, Human molecular genetics.

[21]  L. Tsui,et al.  Physical localization of two DNA markers closely linked to the cystic fibrosis locus by pulsed-field gel electrophoresis. , 1989, American journal of human genetics.

[22]  L. Tsui,et al.  Erratum: Identification of the Cystic Fibrosis Gene: Genetic Analysis , 1989, Science.

[23]  L. Tsui,et al.  Erratum: Identification of the Cystic Fibrosis Gene: Cloning and Characterization of Complementary DNA , 1989, Science.

[24]  J. Burke,et al.  Suppression of a nonsense mutation in mammalian cells in vivo by the aminoglycoside antibiotics G-418 and paromomycin. , 1985, Nucleic acids research.